Option chain shows key data for Alzamend Neuro's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Alzamend Neuro.

Alzamend Neuro (NASDAQ:ALZN) Stock, Option Chain

ALZAMEND NEURO INC

Alzamend Neuro

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Blood,Test.,Doctor,Working,With,Patient's,Blood,Sample,In,Lab.

News

ALZN

Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims for improved brain delivery and fewer side effects.

Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone

Crude,Oil,Pump,Jack,At,Oilfield,On,Sunset,Backround.,Fossil

Earnings

Equities

Eurozone

Commodities

Markets

Trading Ideas

EOSE

ORIC

REVB

STRM

Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results

Nasdaq,Inscription,Next,To,Us,Dollars.,The,Nasdaq,Is,An

BROG

ELPW

HCTI

NVDA

Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue

Alzamend Neuro Inc

Health Care

Press Releases

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

General

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Synergy CHC Corp. (NASDAQ: SNYR) Taps Beverage Veteran to Drive FOCUSfactor's Drink Expansion – More Stocks Inside

Financing

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

AMZN

COST

HTCR

NAOV

SNYR

Aditxt

Aptevo Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

NuCana

Oragenics

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Plus Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Ascendiant Capital

Maxim Group

Comments

Alzamend Neuro

Alzamend Neuro (ALZN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell